Dosing and infusion rates

Privigen is a ready-to-use 10% liquid intravenous immunoglobulin (IVIg) with no warming or reconstitution necessary. It should be given by a separate infusion line and not mixed with other intravenous medications*. See the chart below, or use the dosing calculator, to find the correct dosage for your patient.
*Privigen may be diluted with Dextrose Injection, USP (D5W).

Recommended dosing and infusion rates

Indication PI ITP
Dose 200–800 mg/kg (2–8 mL/kg) every 3–4 weeks 1 g/kg (10 mL/kg) daily for 2 consecutive days
Initial infusion rate 0.5 mg/kg/min (0.005 mL/kg/min) 0.5 mg/kg/min (0.005/mL/kg/min)
Maximum infusion rate (if tolerated) Increase to 8 mg/kg/min (0.08 mL/kg/min) Increase to 4 mg/kg/min (0.04 mL/kg/min)
Indication Dose Initial infusion rate Maximum infusion rate (if tolerated)
PI 200–800 mg/kg (2–8 mL/kg) every 3–4 weeks 0.5 mg/kg/min (0.005 mL/kg/min) Increase to 8 mg/kg/min (0.08 mL/kg/min)
Chronic ITP 1 g/kg (10 mL/kg) daily for 2 consecutive days 0.5 mg/kg/min (0.005/mL/kg/min) Increase to 4 mg/kg/min (0.04 mL/kg/min)

Monitor the patient’s vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Dosing calculator

Dosing Calculator Step 1 Patient Profile
ITP Dose: 1 g/kg (10 mL/kg) daily for 2 consecutive days
PI Dose: 200–800 mg/kg (2–8 mL/kg) every 3–4 weeks
Please round to the nearest whole number.
Dosing Calculator Step 2 Infusion Rate
0.3
min
2.4
max
4.8
max
2.4 mL/kg/h
Initial 0.5 mg/kg/min
(0.005 mL/kg/min)
Maintenance
(as tolerated)
Increase to 4 mg/kg/min
(0.04 mL/kg/min)
Initial 0.5 mg/kg/min
(0.005 mL/kg/min)
Maintenance
(as tolerated)
Increase to 8 mg/kg/min
(0.08 mL/kg/min)
For patients at risk for renal dysfunction or thrombosis or patients switching from another Ig product, always start at the minimum dose and infusion rate.
Back
Dosing Calculator Step 3 Calculated
Infusion Rate
000 mL/h
Total Dose: mL
Infusion Time:
  • Monitor the patient’s vital signs throughout the infusion.
  • Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.
  • Titrate based on patient tolerability.
Back

Please consult the prescribing information for complete dosing and infusion information.

Download a PDF of dosing and infusion rates based on patient weight or use the calculator above to find precise dosing information for each patient.

Download the Privigen infusion rates brochure

Order Privigen now

To order, please contact your GPO or distributor. Privigen is available in these four convenient vial sizes:

Order Privigen from your GPO or distributor
Grams 5
Fill Size (mL) 50
NDC Number 44206-436-05
Order Privigen from your GPO or distributor
Grams 10
Fill Size (mL) 100
NDC Number 44206-437-10
Order Privigen from your GPO or distributor
Grams 20
Fill Size (mL) 200
NDC Number 44206-438-20
Order Privigen from your GPO or distributor
Grams 40
Fill Size (mL) 400
NDC Number 44206-439-40
IgIQ

IgIQ: Get help with ordering, billing, coding, and reimbursement

IgIQ can help. It’s your single source for Ig solutions from CSL Behring. Find out more or call 877-355-4447 to speak with an expert.

Starting new patients on Privigen

When starting new patients on Privigen therapy:

  • Privigen should be administered at the minimum dose and infusion rate practicable in patients judged to be at risk of renal failure, renal dysfunction, or thrombotic events
  • Patients at risk of thrombosis, renal dysfunction, or renal failure should not be volume depleted when initiating intravenous immunoglobulin (IVIg) therapy. Ensure adequate hydration before administering Privigen
  • The patient's vital signs should be monitored carefully throughout the infusion for adverse reactions
  • If adverse reations occur, the infusion should be stopped or slowed down until the symptoms subside, and may be resumed at a more comfortable, lower rate

Transitioning patients from another IVIg product to Privigen

If you are transitioning patients from another IVIg product to Privigen:

  • Always start at the minimum rate of infusion
  • The patient's vital signs should be monitored carefully throughout the infusion for adverse reactions
  • If adverse reactions occur, the infusion should be stopped or slowed down until the symptoms subside, and may be resumed at a more comfortable, lower rate
  • Titrate based on patient tolerability

Monitoring patients for adverse reactions

Patients receiving Privigen should be observed and monitored carefully throughout the infusion. If adverse reactions occur, the infusion should be slowed or stopped until the symptoms subside. The infusion may then be resumed at a lower rate that is comfortable for the patient. Following are some other things to keep in mind:

  • Warnings and Precautions
    • Immunoglobulin A (IgA)-deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions
    • Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure
    • Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIg therapy
    • Thrombotic events may occur. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk for hyperviscosity
    • Aseptic meningitis syndrome may occur, especially with high doses or rapid infusion
    • Hemolysis can develop subsequent to Privigen treatments due to enhanced red blood cell sequestration. Monitor patients for hemolysis and hemolytic anemia
    • Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI])
    • Avoid use of the high-dose regimen (for chronic immune thrombocytopenic purpura [ITP]) in patients with expanded fluid volume or where fluid volume is of concern
    • Privigen is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated
    • Passive transfer of antibodies may confound serologic testing

Please see Important Safety Information and full prescribing information.

  • Therapy Contraindications

Privigen is contraindicated in patients with history of anaphylactic or severe systemic reaction to human immune globulin, in patients with hyperprolinemia, and in IgA-deficient patients with antibodies to IgA and history of hypersensitivity.

  • Renal Failure Warning

Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with the administration of Immune Globulin Intravenous (Human) (IVIg) products in predisposed patients. Administer IVIg products at the minimum dose and infusion rate possible. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Privigen does not contain sucrose.

You are now leaving the current website.

Do you want to continue?